Literature DB >> 2945891

Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.

C Van Waes, J L Urban, J L Rothstein, P L Ward, H Schreiber.   

Abstract

We have studied the components of a complex of tumor-specific antigens to determine if all of the components of the complex were lost during progression from a rather benign regressor tumor to a highly malignant (HM) cancer. We find that the HM tumor cells have lost antigens recognized by CTL but retained antigens recognized by Th cells. Immunization with variants expressing Th-defined antigens induced tumor-specific immunity to challenge with a parental variant that expressed a CTL-recognized target antigen, but did not induce immunity to challenge with the variant that expressed the Th-defined antigen alone. Together, these findings suggested that Th cells fail to exert direct selective pressure upon the tumor, resulting in retention of "lineage-specific," Th-recognized antigens by highly immunoselected variants. Possible advantage could be taken of this fact for the development of specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945891      PMCID: PMC2188458          DOI: 10.1084/jem.164.5.1547

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  The immune response and the homograft reaction.

Authors:  H J WINN
Journal:  Natl Cancer Inst Monogr       Date:  1960-03

2.  Quantitative studies on tissue transplantation immunity. 8. The effects of irradiation.

Authors:  L Brent; P Medawar
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-10-11

3.  The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.

Authors:  H Fujiwara; Y Takai; K Sakamoto; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

4.  Lymphotoxin production by subsets of T cells.

Authors:  D D Eardley; F W Shen; R K Gershon; N H Ruddle
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

5.  Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis.

Authors:  J P Tite; C A Janeway
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

6.  Pecking order among tumor-specific antigens.

Authors:  J L Urban; C Van Waes; H Schreiber
Journal:  Eur J Immunol       Date:  1984-02       Impact factor: 5.532

7.  Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.

Authors:  C Philipps; M McMillan; P M Flood; D B Murphy; J Forman; D Lancki; J E Womack; R S Goodenow; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

8.  Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.

Authors:  R D Wortzel; J L Urban; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  A comparison of four methods for measuring cutaneous delayed- type hypersensitivity reactions to protein antigens in the mouse.

Authors:  J H Robinson; J D Naysmith
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

10.  Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism.

Authors:  N H Ruddle; B H Waksman
Journal:  J Exp Med       Date:  1968-12-01       Impact factor: 14.307

View more
  11 in total

1.  Generation of a T-cell hybridoma producing a contrasuppressor factor for contact sensitivity.

Authors:  A M Friedman; W Ptak; E Brewer; D R Green; P A Reuter; P M Flood
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

2.  Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction.

Authors:  Z Chen; C W Smith; D Kiel; C Van Waes
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

3.  Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Authors:  Jay Friedman; Ellen C Moore; Paul Zolkind; Yvette Robbins; Paul E Clavijo; Lilian Sun; Sarah Greene; Megan V Morisada; Wojciech K Mydlarz; Nicole Schmitt; James W Hodge; Hans Schreiber; Carter Van Waes; Ravindra Uppaluri; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-10-23       Impact factor: 12.531

4.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.

Authors:  G B Beck-Engeser; P A Monach; D Mumberg; F Yang; S Wanderling; K Schreiber; R Espinosa; M M Le Beau; S C Meredith; H Schreiber
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

6.  Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.

Authors:  S Jung; H J Schluesener
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

7.  Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.

Authors:  H J Stauss; C Van Waes; M A Fink; B Starr; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

8.  A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.

Authors:  S Seung; J L Urban; H Schreiber
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

9.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

Authors:  S Singh; S R Ross; M Acena; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

10.  Immunogenic capacity of tum--variants isolated from a rat rhabdomyosarcoma.

Authors:  C Pauwels-Vergely; M F Poupon
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.